Home/Pipeline/GCS002

GCS002

Atopic dermatitis

DiscoveryActive

Key Facts

Indication

Atopic dermatitis

Phase

Discovery

Status

Active

Company

Glen Clova Scientific

About Glen Clova Scientific

Glen Clova Scientific is a private, preclinical-stage biotech leveraging a proprietary Virus-Like Particle (VLP) platform to develop therapeutic vaccines. Its technology is designed to induce natural antibody responses with drastically lower dosing requirements and cost of goods compared to conventional biologics, targeting improved accessibility in both human and veterinary medicine. The lead program, GCS001 for senile pruritus, is slated to enter clinical trials in 2026. The company operates from Dundee, UK, and appears to be pre-revenue, focusing on R&D and potential partnerships.

View full company profile

Therapeutic Areas

Inflammatory Diseases Dermatology Veterinary Medicine

Other Atopic dermatitis Drugs

Drug	Company	Phase	Status
PEP Biologic™	Intent Biologics	Unknown	Active
HBM7575 (SKB575)	Harbour BioMed	IND Filed	Active (Global)
ITK inhibitor	Acellera	Pre-clinical	Hit-to-Lead
ENS-002 (Fermata Derm)	Concerto Biosciences	Pre-clinical	Active
Lead Program	MatriSys Bioscience	Phase 1	Active
Atopic Dermatitis Trial	Well Pharma Medical Research	Not Specified	Active
MEndoB	Micreos	Pre-clinical	Active
Atopic Dermatitis Program	Lxbio Pharmaceuticals	Pre-clinical	Active
B244	AOBiome	Phase 3	Active
CTO1681	CytoAgents	Pre-clinical	Active
DS107	DS Biopharma	Phase 2	Active
AX-158	Artax Biopharma	Phase 2	Active